EGFR T790M mutation: a double role in lung cancer cell survival?
about
Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cellsRole of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsIrreversible EGFR-TKIs: dreaming perfectionThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerSignaling cross-talk in the resistance to HER family receptor targeted therapyThe impact of the Cancer Genome Atlas on lung cancer.Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutationsOsimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyGerm-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsImportance of molecular features of non-small cell lung cancer for choice of treatment.Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitorsUp-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib.T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapyMechanisms of resistance to EGFR tyrosine kinase inhibitors.Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.Erlotinib resistance in lung cancer: current progress and future perspectives.Development of a novel, fully-automated genotyping system: principle and applications.EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.Novel biomarkers of metastatic cancer.Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.Personalized medicine for lung cancer: new challenges for pathology.Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Target Therapy in Lung Cancer.Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.Afatinib in squamous cell carcinoma of the head and neck.Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond.Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
P2860
Q24309725-8098D134-5777-4864-A667-048F712F98F4Q26750428-30662380-C0B9-4421-9614-EE12772F6CFAQ26820845-58556D5C-2433-49F0-B010-3AA3DFE773EEQ26866186-62873898-2A86-4905-8A0A-94855FABDB7DQ27021738-5173281E-E1CD-4641-981A-EEF6ADD8289FQ27027778-52691B89-C0C3-4D9D-B9A5-58230029DB88Q28084190-6869BD55-3243-4EE7-8DFB-EEEDDD6AA64BQ28384015-703D2B11-BFFE-4A7C-BFCE-004EDDAF7437Q33757134-B56DEFAE-DA2A-4909-9D2F-F844B0D8068AQ33901617-E715DE98-EEA7-4B10-9CDF-75B21F5BF230Q34092157-E1D8367A-AB33-40E4-8791-6EA2DE0063D2Q34564071-875F82DA-7A43-4FD2-9E63-58A05DEA0859Q34838412-05781C42-D2CF-454F-A6AC-FE0B3E7C7CADQ35016912-860540B3-8861-4380-ACD0-BDA719C9ADA3Q35116206-43CE0AB0-0D8C-4D84-AE13-04BE827CD728Q35600765-146BF81F-820D-4444-86B9-B02DE4272AE8Q35667787-801A5607-B478-4A00-B3D3-5B6A5BBCA7F6Q35749960-950F8F32-A5D3-43F5-A3D8-53BE5EC8A38AQ36071392-F772FC93-187F-4630-838C-EBE7D16DADBAQ36238664-9AF8CD72-A07A-4215-91FC-48EE03105668Q36473360-0576616E-0C70-48F7-A03C-EA169A33A96EQ36567573-76165BB6-AB79-48EF-9C92-0739E881E10AQ36605522-63107361-3E23-41B9-BD48-FEC09D4561EAQ36608218-5E8B8B16-935D-4308-97D3-788B3B501D15Q36619212-A5053280-423F-450A-94A4-85EF089CD157Q37212135-DA6D7D96-86A6-486C-AD0B-4F5032BB2F69Q37772496-E3A5B373-4B50-4DBF-A625-DABC1D1EC9C2Q37799825-1D901992-BAA4-434B-B532-DAFD553B466CQ37823422-91F116D3-E066-4018-B80C-33851518756AQ37932029-AFFBC525-D2A0-433B-825C-DCAEA274E630Q38021967-08C5B7A0-1E16-4276-BF12-E0CCAAD60EDDQ38263419-F8F07255-AD73-4664-BBC3-ED8AF1F2C8BBQ38437895-3FD7B783-B592-46C6-B448-C685242F0CD0Q38486882-F3F62E5D-1DC7-4793-9B36-B7DF34F654D6Q38584814-22F0AA0F-9652-4BD0-879C-5DEACA3FA7E6Q38669277-622A0F59-F216-4D82-81BF-40C6F1E43B7AQ38669280-B7A10485-8A17-4A31-9B73-5CDEEF6AA900Q38829891-5F6F69D3-413B-464B-A11E-94135D413ADCQ38956309-0CFB63BC-0458-49FD-98E2-485D6649BA03Q38982951-D5FBCDDC-714B-4484-B3A9-C685EFC4B3F0
P2860
EGFR T790M mutation: a double role in lung cancer cell survival?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EGFR T790M mutation: a double role in lung cancer cell survival?
@en
EGFR T790M mutation: a double role in lung cancer cell survival?
@nl
type
label
EGFR T790M mutation: a double role in lung cancer cell survival?
@en
EGFR T790M mutation: a double role in lung cancer cell survival?
@nl
prefLabel
EGFR T790M mutation: a double role in lung cancer cell survival?
@en
EGFR T790M mutation: a double role in lung cancer cell survival?
@nl
P50
P1476
EGFR T790M mutation: a double role in lung cancer cell survival?
@en
P2093
Ryoichi Onozato
P356
10.1097/JTO.0B013E3181913C9F
P577
2009-01-01T00:00:00Z